市場調査レポート

ナノメディシンの世界市場(神経科、心血管系、抗炎症、抗感染症、がん科用途) - 産業分析、規模、シェア、成長率、トレンドおよび予測

Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019

発行 Transparency Market Research 商品コード 294638
出版日 ページ情報 英文 81 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.16円で換算しております。
Back to Top
ナノメディシンの世界市場(神経科、心血管系、抗炎症、抗感染症、がん科用途) - 産業分析、規模、シェア、成長率、トレンドおよび予測 Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019
出版日: 2014年01月08日 ページ情報: 英文 81 Pages
概要

当レポートでは、ナノメディシン(ナノ医療)の世界市場に注目し、、神経科、心血管系、抗炎症、抗感染、がん科ほかの各用途および北米、欧州、アジア太平洋州、その他地域の別に、その動向を詳細に分析・検証し、市場の推移および発展性を分析・予測する最新情報、および同市場に活躍する主要企業の概要と競合状況をまとめ、概略以下の構成でお届けします。

第1章 序

  • レポート内容説明
  • 調査方法
  • 市場セグメンテーション

第2章 エグゼクティブサマリー

第3章 ナノメディシンの世界市場概要

  • 市場動態
    • 市場推進要因
      • ナノメディシンを支える技術の向上
      • ナノメディシン分野の研究開発に対する行政支援の強化
      • 高度な医療アンメットニーズの存在
      • 投資とヘルスケア共同事業の増加
      • 多発する慢性疾患
      • 市場推進要因の影響度分析
  • 市場抑制要因
    • 未整備な既成の枠組み
    • 高額な関連コスト
    • 市場抑制要因の影響度分析
  • 市場機会
    • 新興市場における医療アンメットニーズの存在
    • 新たな医療用途の発見
  • Porterのファイブフォース分析:世界のナノメディシン市場
    • 供給者の交渉力
    • 購買者の交渉力
    • 新規参入者の脅威
    • 代替品の脅威
    • 競合
  • 市場求心力分析:世界のナノメディシン市場 - 用途別
  • 世界のナノメディシン市場(単位:100万米ドル)

第4章 世界のナノメディシン市場 - 用途別

  • 概要
  • 神経科ナノメディシン
  • 心血管系ナノメディシン
  • がん科ナノメディシン
  • 抗炎症ナノメディシン
  • 抗感染症ナノメディシン
  • その他の用途
  • 比較分析:世界のナノメディシン市場 - 用途別(%)

第5章 世界のナノメディシン市場 - 地域別

  • 概要
    • 比較分析:世界のナノメディシン市場 - 地域別(%)
  • 北米
  • 欧州
  • アジア太平洋州
  • その他の地域

第6章 提言

  • 学際的教育・訓練の促進に向けた教育機関との協力
  • 重要成長分野の識別と優先化

第7章 企業プロフィール(企業概要、財務概要、製品構成、事業戦略、最近の展開)

  • Abbott Laboratories
  • CombiMatrix Corporation
  • Celgene Corporation
  • Mallinckrodt plc.
  • GE Healthcare
  • Johnson & Johnson
  • Merck & Company Inc.
  • Nanosphere, Inc.
  • Pfizer Inc.
  • Sigma-Tau Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

図表一覧

目次

This report includes market estimations for nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019.

The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report.

The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world.

The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period.

The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

The global nanomedicine market is categorized into the following segments:

Nanomedicine Market by Application

  • Neurology
  • Cardiovascular
  • Anti-Inflammatory
  • Anti-Infectives
  • Oncology
  • Others

Nanomedicine Market by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)

Table of Contents

Chapter 1 Preface

  • 1.1 Report description
  • 1.2 Research Methodology
  • 1.3 Market Segmentation

Chapter 2 Executive Summary

Chapter 3 Global Nanomedicine Market Overview

  • 3.1 Market Dynamics
    • 3.1.1 Market Drivers
      • 3.1.1.1 Improvement in technology for nanomedicine
      • 3.1.1.2 Rising government support for research and development in nanomedicine
      • 3.1.1.3 Presence of high unmet medical needs
      • 3.1.1.4 Increase in investment amount and healthcare collaborations
      • 3.1.1.5 High prevalence of chronic diseases
      • 3.1.1.6 Impact Analysis of the Market Drivers
    • 3.1.2 Market Restraints
      • 3.1.2.1 Lack of organized regulatory framework
      • 3.1.2.2 High costs involved
      • 3.1.2.3 Impact Analysis of the Market Restraints
    • 3.1.3 Market Opportunities
      • 3.1.3.1 Presence of unmet medical needs in emerging economies
      • 3.1.3.2 Identification of new medical applications
  • 3.2 Porter's Five Forces Analysis: Global Nanomedicine Market
    • 3.2.1 Bargaining Power of Suppliers
    • 3.2.2 Bargaining Power of Buyers
    • 3.2.3 Threat of New entrants
    • 3.2.4 Threat of Substitutes
    • 3.2.5 Competitive Rivalry
  • 3.3 Market Attractiveness Analysis of the Global Nanomedicine Market, by Application
  • 3.4 Global Nanomedicine Market, 2011 - 2019 (USD Million)

Chapter 4 Global Nanomedicine Market, by Applications

  • 4.1 Overview
  • 4.2 Nanomedicine for Neurology
    • 4.2.1 Global Nanomedicine for Neurology Market, 2011 - 2019 (USD Billion)
    • 4.3 Nanomedicine for Cardiovascular (CVS)
  • 4.3.1 Global Nanomedicine for Cardiovascular Market , 2011 - 2019 (USD Billion)
  • 4.4 Nanomedicine for Oncology
    • 4.4.1 Global Nanomedicine for Oncology Market , 2011 - 2019 (USD Billion)
  • 4.5 Nanomedicine for Anti-inflammatory
    • 4.5.1 Global Nanomedicine for Anti-Inflammatory Market, 2011 - 2019 (USD Billion)
  • 4.6 Nanomedicine for Anti-infectives
    • 4.6.1 Global Nanomedicine for Anti-Infectives Market, 2011 - 2019 (USD Billion)
  • 4.7 Other Applications
    • 4.7.1 Global Nanomedicine Market for Other Applications, 2011 - 2019 (USD Billion)
  • 4.8 Comparative Analysis: Global Nanomedicine Market by Applications, 2012 & 2019 (%)

Chapter 5 Global Nanomedicine Market, by Geography

  • 5.1 Overview
    • 5.1.1 Comparative Analysis of the Global Nanomedicine Market, by Geography, 2012 & 2019 (%)
  • 5.2 North America
    • 5.2.1 North America Nanomedicine Market, 2011 - 2019 (USD Billion)
  • 5.3 Europe
    • 5.3.1 Europe Nanomedicine Market, 2011 - 2019 (USD Billion)
  • 5.4 Asia-Pacific
    • 5.4.1 Asia-Pacific Nanomedicine Market, 2011 - 2019 (USD Billion)
  • 5.5 Rest of the World
    • 5.5.1 Rest of the World Nanomedicine Market, 2011 - 2019 (USD Billion)

Chapter 6 Recommendations

  • 6.1 Collaborating with educational institutions to boost interdisciplinary education and training
  • 6.2 Identifying and prioritizing key growth areas

Chapter 7 Company Profiles

  • 7.1 Abbott Laboratories
    • 7.1.1 Company Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Product Portfolio
    • 7.1.4 Business Strategies
    • 7.1.5 Recent Developments
  • 7.2 CombiMatrix Corporation
    • 7.2.1 Company Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Product Portfolio
    • 7.2.4 Business Strategy
    • 7.2.5 Recent Developments
  • 7.3 Celgene Corporation
    • 7.3.1 Company Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Product Portfolio
    • 7.3.4 Business Strategies
    • 7.3.5 Recent Developments
  • 7.4 Mallinckrodt plc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Product Portfolio
    • 7.4.4 Business Strategies
    • 7.4.5 Recent Developments
  • 7.5 GE Healthcare
    • 7.5.1 Company Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Product Portfolio
    • 7.5.4 Business Strategies
    • 7.5.5 Recent Developments
  • 7.6 Johnson & Johnson
    • 7.6.1 Company Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Product Portfolio
    • 7.6.4 Business Strategies
    • 7.6.5 Recent Developments
  • 7.7 Merck & Company Inc.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Overview
    • 7.7.3 Product Portfolio
    • 7.7.4 Business Strategies
    • 7.7.5 Recent Developments
  • 7.8 Nanosphere, Inc.
    • 7.8.1 Company Overview
    • 7.8.2 Financial Overview
    • 7.8.3 Product Portfolio
    • 7.8.4 Business Strategies
    • 7.8.5 Recent Developments
  • 7.9 Pfizer Inc.
    • 7.9.1 Company Overview
    • 7.9.2 Financial Overview
    • 7.9.3 Product Portfolio
    • 7.9.4 Business Strategies
  • 7.10 Sigma-Tau Pharmaceuticals Inc.
    • 7.10.1 Company Overview
    • 7.10.2 Financial Overview
    • 7.10.3 Product Portfolio
    • 7.10.4 Business Strategies
    • 7.10.5 Recent Developments
  • 7.11 Teva Pharmaceutical Industries Ltd.
    • 7.11.1 Company Overview
    • 7.11.2 Financial Overview
    • 7.11.3 Product Portfolio
    • 7.11.4 Business Strategy
    • 7.11.5 Recent Developments
  • 7.12 UCB SA
    • 7.12.1 Company Overview
    • 7.12.2 Financial Overview
    • 7.12.3 Product Portfolio
    • 7.12.4 Business Strategies
    • 7.12.5 Recent Developments

List of Figures

  • FIG. 1 Market Segmentation for the Nanomedicine Market
  • FIG. 2 Global Nanomedicine Market, by Application and Geography, 2012 (USD Billion)
  • FIG. 3 Porter's Five Forces Analysis: Global Nanomedicine Market
  • FIG. 4 Market Attractiveness Analysis of the Global Nanomedicine Market, by Application
  • FIG. 5 Global Nanomedicine Market, 2011 - 2019 (USD Billion)
  • FIG. 6 Global Nanomedicine for Neurology Market, 2011 - 2019 (USD Billion)
  • FIG. 7 Global Nanomedicine for Cardiovascular Market, 2011 - 2019 (USD Billion)
  • FIG. 8 Global Nanomedicine for Oncology Market, 2011 - 2019 (USD Billion)
  • FIG. 9 Global Nanomedicine for Anti-Inflammatory Market, 2011 - 2019 (USD Billion)
  • FIG. 10 Global Nanomedicine for Anti-Infective Market, 2011 - 2019 (USD Billion)
  • FIG. 11 Global Nanomedicine Market for Other Applications, 2011 - 2019 (USD Billion)
  • FIG. 12 Comparative Analysis: Global Nanomedicine Market by Applications, 2012 & 2019 (Value %)
  • FIG. 13 Comparative Analysis of the Global Nanomedicine Market, by Geography, 2012 & 2019 (%)
  • FIG. 14 North America Nanomedicine Market, 2011 - 2019 (USD Billion)
  • FIG. 15 Europe Nanomedicine Market, 2011 - 2019 (USD Billion)
  • FIG. 16 Asia-Pacific Nanomedicine Market, 2011 - 2019 (USD Billion)
  • FIG. 17 Rest of the World Nanomedicine Market, 2011 - 2019 (USD Billion)
  • FIG. 18 Abbott Laboratories: Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 19 CombiMatrix Corporation: Annual Sales, 2010 - 2012 (USD Million)
  • FIG. 20 Celgene Corporation: Annual Sales, 2010 - 2012 (USD Million)
  • FIG. 21 Covidien Plc.: - Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 22 GE Healthcare: Annual Revenue, 2010-2012 (USD Million)
  • FIG. 23 Johnson & Johnson: Medical Devices and Diagnostic Business Segment, Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 24 Merck & Co. Inc.: Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 25 Nanosphere Inc.: Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 26 Pfizer Inc.: Annual Revenue, 2010 - 2012 (USD Million)
  • FIG. 27 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2010-2012 (USD Million)
  • FIG. 28 UCB S.A.: Annual Revenue, 2010 - 2012 (USD Million)

List of Tables

  • TABLE 1 Market Snapshot: Global Nanomedicine Market
  • TABLE 2 Impact Analysis of the Market Drivers for the Global Nanomedicine Market
  • TABLE 3 Impact Analysis of the Market Restraints for the Global Nanomedicine Market
  • TABLE 1 Global Nanomedicine Market, by Applications, 2011 -2019 (USD Billion)
  • TABLE 2 Global Nanomedicine Market, by Geography, 2011 - 2019 (USD Billion)
Back to Top